Cholesterol lowering statins: Scope for use widens

Dr Upul Wijayawardhana, a physician with over half a century of experience in medicine, recalls a remarkable patient who demonstrated the potential dangers of ignoring prescription warnings. This patient, a man in his sixties, was admitted to Grantham Hospital with severe muscle pain and weakness, displaying extensive muscle damage.

The patient was on long-term statin therapy following a heart attack, and had recently been prescribed an antifungal medication for a groin infection. The antifungal drug, prior to the era of computerized prescriptions, would have likely triggered severe drug interactions with the statin. Both medications were discontinued, and the patient recovered swiftly.

Wijayawardhana emphasizes that while statins can cause side effects, their benefits far outweigh these risks. He argues that despite the occasional negative attention, statins remain the most widely used class of drugs and their scope for use is expanding due to the release of new clinical trials. Two significant trials were presented at the European Society of Cardiology Congress held in Munich; one being the STAREE study, which enrolled 5000 individuals over 70 in Australia with no history of cardiovascular disease, diabetes, or dementia.

The study found a 30% reduction in the composite end point of death from cardiovascular causes, nonfatal myocardial infarction, stroke, or coronary revascularization among those who received atorvastatin 40mg daily compared to a placebo. Another Danish observational study revealed a 15% lower risk of dementia in individuals who initiated statin treatment early after a type 2 diabetes diagnosis.